Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Astellas Pharma and Daiichi Sankyo Form Compound Library Sharing Partnership

Published: Saturday, March 22, 2014
Last Updated: Saturday, March 22, 2014
Bookmark and Share
Both Companies will exchange approximately 400,000 selected compounds.

Astellas Pharma Inc. and Daiichi Sankyo Company, Limited have announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds.

The collaboration enables each party to promote innovative new medicine research and development. This is the first time that a compound library partnership of this scale has been formed in Japan.

Astellas and Daiichi Sankyo have compound libraries that are the basis for their drug discovery research, and through High Throughput Screening (HTS), the companies can quickly and effectively search for potentially beneficial compounds to develop innovative new drugs.

Extensive, diverse, and high-quality compound libraries, such as the joint Astellas/Daiichi Sankyo libraries, are crucial to successful drug discovery.

This partnership will give each company access to qualitatively different compound libraries-which have been developed based on the targeting disease strategies of each company-allowing both companies to implement broader HTS to generate innovative new drugs.

Under this partnership, Astellas and Daiichi Sankyo will exchange approximately 400,000 selected compounds, including a significant number of proprietary synthetic compounds, from their respective compound libraries. Beginning April 1, 2014, for a period of three years, both Astellas and Daiichi Sankyo will be able to implement broad HTS using the shared compounds without restrictions on targeted disease areas. In line with the partnership, each company will disclose sufficient information to allow the receiving company to implement HTS independently.

If, as a result of HTS, the receiving company identifies a candidate compound to be used for a new drug discovery, the receiving company may carry out development and commercialization of the innovative new drug with an indication for any human diseases from the compound pursuant to the terms of agreement.

Astellas and Daiichi Sankyo have each set forth a corporate philosophy to contribute to the health of people around the world. Through this partnership, both companies aim to effectively utilize each other’s assets and knowledge beyond the framework of one pharmaceutical company, and accelerate open innovation while taking advantage of their own internal strengths to provide innovative new drugs.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Astellas Pharma and BioFocus Sign Target Discovery Agreement
Collaboration agreement with Astellas focused on discovering novel targets in the field of CNS disorders.
Friday, May 13, 2011
Astellas Pharma Europe Appoints Ken Jones as President and CEO
Ken Jones succeeds Mr Masao Yoshida, who has been appointed as President and CEO of Astellas Pharma US, Inc.
Tuesday, April 19, 2011
Astellas Begins Screening Another Target From Metabolex Gene Database
Initiation of screening against unique target triggers milestone payment to Metabolex.
Monday, September 18, 2006
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Light of Fireflies for Medical Diagnostics
EPFL scientists have exploited the light of fireflies in a new method that detects biological molecules without the need for complex devices and high costs.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!